The DOI matches its Crossref record; 317 of the 317 references it cites were found in a registry or an index.
Localized Interleukin-12 for Cancer Immunotherapy
Open accessAbstract
Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable antitumor efficacy in preclinical models has yet to be replicated in humans. Early clinical trials in the mid-1990's showed that systemic delivery of IL-12 incurred dose-limiting toxicities. Nevertheless, IL-12's pleiotropic activity, i.e., its ability to engage multiple effector mechanisms and reverse tumor-induced immunosuppression, continues to entice cancer researchers. The development of strategies which maximize IL-12 delivery to the tumor microenvironment while minimizing systemic exposure are of increasing interest. Diverse IL-12 delivery systems, from immunocytokine fusions to polymeric nanoparticles, have demonstrated robust antitumor immunity with reduced adverse events in preclinical studies. Several localized IL-12 delivery approaches have recently reached the clinical stage with several more at the precipice of translation. Taken together, localized delivery systems are supporting an IL-12 renaissance which may finally allow this potent cytokine to fulfill its considerable clinical potential. This review begins with a brief historical account of cytokine monotherapies and describes how IL-12 went from promising new cure to ostracized black sheep following multiple on-study deaths. The bulk of this comprehensive review focuses on developments in diverse localized delivery strategies for IL-12-based cancer immunotherapies. Advantages and limitations of different delivery technologies are highlighted. Finally, perspectives on how IL-12-based immunotherapies may be utilized for widespread clinical application in the very near future are offered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Designing hydrogels for controlled drug delivery
Li, J., & Mooney, D. J. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.71 · Cited by 4,832
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · cited 1×
“Standard protocols for ex vivo expansion of tumor infiltrating lymphocytes for adoptive cell therapy (ACT) traditionally used high dose IL2 to facilitate T cell proliferation (70).”
MethodAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Thermal ablation of tumours: biological mechanisms and advances in therapy
Chu, K. F., & Dupuy, D. E. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3672 · Cited by 1,988
Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., & Trinchieri, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.827 · Cited by 1,953
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Wolf, S. F., Temple, P. A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., Dzialo, R., Fitz, L., Ferenz, C., & Hewick, R. M. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.9.3074 · Cited by 845
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Surgery for Cancer: A Trigger for Metastases
Tohme, S., Simmons, R. L., & Tsung, A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1536 · Cited by 779
Fu, K., Pack, D. W., Klibanov, A. M., & Langer, R. (2000) · Pharmaceutical Research · doi:10.1023/a:1007582911958 · Cited by 764
Evaluation of the biocompatibility of a chitosan scaffold in mice
VandeVord, P. J., Matthew, H. W. T., DeSilva, S. P., Mayton, L., Wu, B., & Wooley, P. H. (2002) · Journal of Biomedical Materials Research · doi:10.1002/jbm.1270 · Cited by 747
Inhibition of Angiogenesis In Vivo by Interleukin 12
Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., & Folkman, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.581 · Cited by 722
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6794 · Cited by 701
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide)
Zhu, G., Mallery, S. R., & Schwendeman, S. P. (2000) · Nature Biotechnology · doi:10.1038/71916 · Cited by 609
Atkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 583
Gubler, U., Chua, A. O., Schoenhaut, D. S., Dwyer, C. M., McComas, W., Motyka, R., Nabavi, N., Wolitzky, A. G., Quinn, P. M., & Familletti, P. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4143 · Cited by 576
Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Donehower, R. C., Jaffee, E. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829fb7a2 · Cited by 564
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Collart, M. A., Belin, D., Vassalli, J. D., de Kossodo, S., & Vassalli, P. (1986) · The Journal of experimental medicine · doi:10.1084/jem.164.6.2113 · Cited by 524
Recent advances in hydrogel based drug delivery systems for the human body
Vashist, A., Vashist, A., Gupta, Y. K., & Ahmad, S. (2014) · J. Mater. Chem. B · doi:10.1039/c3tb21016b · Cited by 499
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Cloning and expression of murine IL-12
Schoenhaut, D. S., Chua, A. O., Wolitzky, A. G., Quinn, P. M., Dwyer, C. M., McComas, W., Familletti, P. C., Gately, M. K., & Gubler, U. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.11.3433 · Cited by 470
Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., & Darnell, J. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7673 · Cited by 422
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Gajewski, T. F., Woo, S.-R., Zha, Y., Spaapen, R., Zheng, Y., Corrales, L., & Spranger, S. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.009 · Cited by 422
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
Krishna, M., & Nadler, S. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00021 · Cited by 389
Challenges in Development of Targeted Liposomal Therapeutics
Sawant, R. R., & Torchilin, V. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9330-0 · Cited by 379
Yang, Q., Jacobs, T. M., McCallen, J. D., Moore, D. T., Huckaby, J. T., Edelstein, J. N., & Lai, S. K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03437 · Cited by 370
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040557897 · Cited by 332
Tahara, H., Zeh, H. J., Storkus, W. J., Pappo, I., Watkins, S. C., Gubler, U., Wolf, S. F., Robbins, P., & Lotze, M. T. (1994) · PubMed · Cited by 326
Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320
Immunogenic effects of chemotherapy-induced tumor cell death
Wang, Y.-J., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 314
Koneru, M., O’Cearbhaill, R., Pendharkar, S., Spriggs, D. R., & Brentjens, R. J. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0460-x · Cited by 302
The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent
Smyth, M. J., Taniguchi, M., & Street, S. E. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2665 · Cited by 301
Polyethylenimine: A versatile, multifunctional non-viral vector for nucleic acid delivery
Pandey, A. P., & Sawant, K. K. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.07.066 · Cited by 300
Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., & Zardi, L. (2002) · Blood · doi:10.1182/blood.v99.5.1659 · Cited by 296
Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Gollob, J., Mier, J. W., Veenstra, K. G., McDermott, D. F., Clancy, D., Clancy, M., & Atkins, M. B. (2000) · PubMed · Cited by 285
Rook, A. H., Wood, G. S., Yoo, E. K., Elenitsas, R., Kao, D. M. F., Sherman, M. L., Witmer, W. K., Rockwell, K. A., Shane, R. B., Lessin, S. R., et al. (1999) · Blood · doi:10.1182/blood.v94.3.902.415k23_902_908 · Cited by 277
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
Watkins, S. K., Egilmez, N. K., Suttles, J., & Stout, R. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1357 · Cited by 273
Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
Zhao, J., Wen, X., Tian, L., Li, T., Xu, C., Wen, X., Melancon, M. P., Gupta, S., Shen, B., Peng, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08782-1 · Cited by 272
Retinoic acid receptors and cancers
Soprano, D. R., Qin, P., & Soprano, K. J. (2004) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.24.012003.132407 · Cited by 270
STUDIES ON THE PATHOGENESIS OF FEVER
Bennett, I. L., Beeson, P. B., & Roberts, W. T. T. A. O. E. (1953) · Journal of Experimental Medicine · doi:10.1084/jem.98.5.493 · Cited by 263
Chiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D. A., Reardon, D. A., Wen, P., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 263
Lucas, M. L., Heller, L., Coppola, D., & Heller, R. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0601 · Cited by 253
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2002) · Nature Biotechnology · doi:10.1038/nbt0302-264 · Cited by 252
Motzer, R. J., Rakhit, A. K., Schwartz, L. H., Olencki, T. E., Malone, T., Sandstrom, K., Nadeau, R., Parmar, H. R., & Bukowski, R. M. (1998) · PubMed · Cited by 251
Hong, M., Puaux, A.-L., Huang, C., Loumagne, L., Tow, C., Mackay, C., Kato, M., Prévost-Blondel, A., Avril, M.-F., Nardin, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1466 · Cited by 246
IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells.
Maraskovsky, E., Chen, W. F., & Shortman, K. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.4.1210 · Cited by 238
Mansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J.-M., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 235
Floros, T., & Tarhini, A. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.015 · Cited by 229
Radiation-induced effects and the immune system in cancer
Kaur, P., & Asea, A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00191 · Cited by 229
Concise Review: Mesenchymal Stem Cell Tumor-Homing: Detection Methods in Disease Model Systems
Reagan, M. R., & Kaplan, D. L. (2011) · Stem Cells · doi:10.1002/stem.645 · Cited by 229
Nishioka, Y., Hirao, M., Robbins, P. D., Lotze, M. T., & Tahara, H. (1999) · PubMed · Cited by 228
Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.
Caruso, M., Pham-Nguyen, K., Kwong, Y. L., Xu, B., Kosai, K. I., Finegold, M., Woo, S. L., & Chen, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11302 · Cited by 227
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
Cheema, T. A., Wakimoto, H., Fecci, P. E., Ning, J., Kuroda, T., Jeyaretna, D. S., Martuza, R. L., & Rabkin, S. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307935110 · Cited by 221
Hayakawa, Y., Takeda, K., Yagita∥, H., Smyth, M. J., Kaer, L. V., Okumura, K., & Saiki, I. (2002) · PubMed · Cited by 219
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
vom Berg, J., Vrohlings, M., Haller, S., Haimovici, A., Kulig, P., Sledzinska, A., Weller, M., & Becher, B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130678 · Cited by 213
Momin, N., Mehta, N. K., Bennett, N. R., Ma, L., Palmeri, J. R., Chinn, M. M., Lutz, E. A., Kang, B., Irvine, D. J., Spranger, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2614 · Cited by 204
Zitvogel, L., Tahara, H., Robbins, P. D., Storkus, W. J., Clarke, M. R., Nalesnik, M. A., & Lotze, M. T. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1393 · Cited by 201
Bramson, J. L., Hitt, M., Addison, C. L., Muller, W. J., Gauldie, J., & Graham, F. L. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.16-1995 · Cited by 188
Immunologic response to cryoablation of breast cancer
Sabel, M. S., Nehs, M. A., Su, G., Lowler, K. P., Ferrara, J. L. M., & Chang, A. E. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-3289-1 · Cited by 188
Nakao, S., Arai, Y., Tasaki, M., Yamashita, M., Murakami, R., Kawase, T., Amino, N., Nakatake, M., Kurosaki, H., Mori, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7992 · Cited by 187
Russell, S. J., & Peng, K.-W. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.005 · Cited by 186
Mazzolini, G., Alfaro, C., Sangro, B., Feijoó, E., Ruiz, J., Benito, A., Tirapu, I., Arina, A., Sola, J., Herraiz, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.463 · Cited by 179
Kueberuwa, G., Kalaitsidou, M., Cheadle, E., Hawkins, R. E., & Gilham, D. E. (2018) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2017.12.003 · Cited by 179
den Brok, M. H. M. G. M., Sutmuller, R. P. M., Nierkens, S., Bennink, E. J., Toonen, L. W. J., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0206 · Cited by 176
Ringel-Scaia, V. M., Beitel-White, N., Lorenzo, M. F., Brock, R. M., Huie, K. E., Coutermarsh-Ott, S., Eden, K., McDaniel, D. K., Verbridge, S. S., Rossmeisl, J. H., et al. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.036 · Cited by 175
Wang, P., Li, X., Wang, J., Gao, D., Li, Y., Li, H., Chu, Y., Zhang, Z., Liu, H., Jiang, G., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01385-8 · Cited by 174
Cavallo, F., Giovarelli, M., Forni, G., Signorelli, P., Musiani, P., Modesti, A., Brunda, M. J., & Colombo, M. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1049 · Cited by 171
Strauss, J., Heery, C. R., Kim, J. W., Jochems, C., Donahue, R. N., Montgomery, A. S., McMahon, S., Lamping, E., Marté, J. L., Madan, R. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1512 · Cited by 171
Nasu, Y., Bangma, C. H., Hull, G. W., Lee, H.-M., Hu, J., Wang, J., McCurdy, M. A., Shimura, S., Yang, G., Timme, T. L., et al. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300834 · Cited by 170
Halin, C., Gafner, V., Villani, M. E., Borsi, L., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2003) · PubMed · Cited by 168
Kim, T. H., Jin, H., Kim, H. W., Cho, M.-H., & Cho, C. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0540 · Cited by 164
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.
Bajetta, E., Vecchio, M. D., Mortarini, R., Nadeau, R., Rakhit, A. K., Rimassa, L., Fowst, C., Borri, A., Anichini, A., & Parmiani, G. (1998) · PubMed · Cited by 163
Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha
Sánchez, A., Tobı́o, M., González, L., Fabra, A., & Alonso, M. J. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00019-8 · Cited by 162
Barajas, M., Mazzolini, G., Genové, G., Bilbao, R., Narvaiza, I., Schmitz, V., Sangro, B., Melero, I., Qian, C., & Prieto, J. (2001) · Hepatology · doi:10.1053/jhep.2001.20796 · Cited by 162
Toda, M., Martuza, R. L., Kojima, H., & Rabkin, S. D. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4457 · Cited by 161
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Algazi, A. P., Twitty, C., Tsai, K. K., Le, M. H., Pierce, R. H., Browning, E., Hermiz, R., Canton, D. A., Bannavong, D., Oglesby, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2217 · Cited by 161
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Fallon, J., Tighe, R., Kradjian, G., Guzman, W., Bernhardt, A., Neuteboom, B., Lan, Y., Sabzevari, H., Schlom, J., & Greiner, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1853 · Cited by 160
Gao, P., Ding, Q., Wu, Z., Jiang, H., & Fang, Z. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.08.031 · Cited by 158
Erinjeri, J. P., Thomas, C. T., Samoilia, A., Fleisher, M., Gönen, M., Sofocleous, C. T., Thornton, R. H., Siegelbaum, R. H., Covey, A. M., Brody, L. A., et al. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2013.02.015 · Cited by 157
Lai, I. K., Swaminathan, S., Baylot, V., Mosley, A. R., Dhanasekaran, R., Gabay, M., & Felsher, D. W. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0431-x · Cited by 156
Heinzerling, L., Burg, G., Dummer, R., Maier, T., Oberholzer, P. A., Schultz, J. G., Elzaouk, L., Pavlovic, J., & Moelling, K. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.35 · Cited by 154
Ryu, C. H., Park, S., Park, S. A., Kim, S. M., Lim, J. Y., Jeong, C. H., Yoon, W., Oh, W., Sung, Y. C., & Jeun, S. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.187 · Cited by 152
Steding, C. E., Wu, S.-T., Zhang, Y.-P., Jeng, M., Elzey, B. D., & Kao, C. H. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03429.x · Cited by 150
Liu, Y., Di, S., Shi, B., Zhang, H., Wang, Y., Wu, X., Luo, H., Wang, H., Li, Z., & Jiang, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800033 · Cited by 150
Seo, S. H., Kim, K. S., Park, S. H., Suh, Y. S., Kim, S. J., Jeun, S.-S., & Sung, Y. C. (2011) · Gene Therapy · doi:10.1038/gt.2010.170 · Cited by 148
Kilinc, M. O., Aulakh, K. S., Nair, R. E., Jones, S. A., Alard, P., Kosiewicz, M. M., & Egilmez, N. K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6962 · Cited by 148
Eigentler, T., Weide, B., de Braud, F., Spitaleri, G., Romanini, A., Pflugfelder, A., González‐Iglesias, R., Tasciotti, A., Giovannoni, L., Schwager, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1203 · Cited by 147
Liu, Y., Yang, M., Luo, J., & Zhou, H. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-00087-0 · Cited by 147
Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model.
Yamashita, Y., Shimada, M. K., Hasegawa, H., et al. (2001) · PubMed · Cited by 145
Chen, L., Chen, D., Block, E., O’Donnell, M. A., Kufe, D. W., & Clinton, S. K. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.351 · Cited by 144
Egilmez, N. K., Jong, Y. S., Sabel, M. S., Jacob, J. S., Mathiowitz, E., & Bankert, R. B. (2000) · PubMed · Cited by 143
Effect of interleukin 12 on tumor induction by 3-methylcholanthrene.
Noguchi, Y., Jungbluth, A., Richards, E. C., & Old, L. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11798 · Cited by 143
Differential Effects of IL-12 on Tregs and Non-Treg T Cells: Roles of IFN-γ, IL-2 and IL-2R
Zhao, J., Zhao, J., & Perlman, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046241 · Cited by 142
Cytokine Gene Transfer Enhances Herpes Oncolytic Therapy in Murine Squamous Cell Carcinoma
Wong, R. J., Patel, S. G., Kim, S., DeMatteo, R. P., Malhotra, S., Bennett, J., St‐Louis, M., Shah, J. P., Johnson, P. A., & Fong, Y. (2001) · Human Gene Therapy · doi:10.1089/10430340150218396 · Cited by 141
Tatsumi, T., Huang, J., Gooding, W. E., Gambotto, A. A., Robbins, P. D., Vujanović, N. L., Alber, S. M., Watkins, S. C., Okada, H., & Storkus, W. J. (2003) · PubMed · Cited by 140
Freedman, A. S., Neelapu, S. S., Nichols, C. R., Robertson, M. J., Djulbegović, B., Winter, J. N., Bender, J. F., Gold, D. P., Ghalie, R., Stewart, M. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8903 · Cited by 138
Algazi, A. P., Bhatia, S., Agarwala, S. S., Molina, M., Lewis, K. D., Faries, M. B., Fong, L. H., Levine, L. P., Franco, M., Oglesby, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.12.008 · Cited by 138
Martini, M., Testi, M. G., Pasetto, M., Picchio, M. C., Innamorati, G., Mazzocco, M., Ugel, S., Cingarlini, S., Bronte, V., Zanovello, P., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.007 · Cited by 137
Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation.
Lohr, F., Lo, D. Y., Zaharoff, D. A., et al. (2001) · PubMed · Cited by 134
Self-citationKang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S., Lee, M. H., Park, K., Kım, K., Jeong, H. S., Kim, J., et al. (2001) · Human Gene Therapy · doi:10.1089/104303401300057388 · Cited by 132
Anti‐tumor activity of mesenchymal stem cells producing IL‐12 in a mouse melanoma model
Elzaouk, L., Moelling, K., & Pavlovic, J. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00479.x · Cited by 130
Motzer, R. J., Rakhit, A. K., Thompson, J. A., Nemunaitis, J. J., Murphy, B. A., Ellerhorst, J. A., Schwartz, L. H., Berg, W. J., & Bukowski, R. M. (2001) · Journal of Interferon & Cytokine Research · doi:10.1089/107999001750169934 · Cited by 127
Hill, H. C., Conway, T. F., Sabel, M. S., Jong, Y. S., Mathiowitz, E., Bankert, R. B., & Egilmez, N. K. (2002) · PubMed · Cited by 125
Carson, W. E., Dierksheide, J. E., Jabbour, S., Anghelina, M. I., Bouchard, P. R., Ku, G., Yu, H., Baumann, H., Shah, M. H., Cooper, M. A., et al. (2000) · Blood · doi:10.1182/blood.v96.4.1465 · Cited by 121
Ahmad, F., Gravante, G. G., Bhardwaj, N., Strickland, A. D., Basit, R., West, K., Sorge, R. P., Dennison, A. R., & Lloyd, D. (2010) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2009.12.025 · Cited by 118
Engineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapy
Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2005) · International Journal of Cancer · doi:10.1002/ijc.20952 · Cited by 117
Quetglas, J. I., Labiano, S., Aznar, M. A., Bolaños, E., Azpilikueta, A., Rodríguez, I., Casales, E., Sánchez-Paulete, A. R., Segura, V., Smerdou, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0216 · Cited by 116
Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma
Little, R. F., Pluda, J. M., Wyvill, K. M., Rodriguez-Chavez, I. R., Tosato, G., Catanzaro, A. T., Steinberg, S. M., & Yarchoan, R. (2006) · Blood · doi:10.1182/blood-2005-11-4455 · Cited by 115
The molecular pathogenesis of Semliki Forest virus: a model virus made useful?
Atkins, G. J., Sheahan, B. J., & Liljeström, P. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-9-2287 · Cited by 115
Intratumoral injection of IL-12 plasmid DNA – results of a phase I/IB clinical trial
Mahvi, D. M., Henry, M. B., Albertini, M. R., Weber, S. M., Meredith, K. L., Schalch, H., Rakhmilevich, A. L., Hank, J. A., & Sondel, P. M. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701064 · Cited by 112
Xu, D., Gu, P., Pan, P., Li, Q., Sato, A. I., & Chen, S. (2004) · International Journal of Cancer · doi:10.1002/ijc.11696 · Cited by 110
Azab, A. K., Doviner, V., Orkin, B., Kleinstern, J., Srebnik, M., Nissan, A., & Rubinstein, A. (2007) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31256 · Cited by 110
Varghese, S., Rabkin, S. D., Liu, R., Nielsen, P., Ipe, T. S., & Martuza, R. L. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700900 · Cited by 110
Bramson, J. L., Hitt, M., Gallichan, W. S., Rosenthal, K. L., Gauldie, J., & Graham, F. L. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.3-333 · Cited by 109
Lucas, M. L., & Heller, R. F. (2003) · DNA and Cell Biology · doi:10.1089/104454903322624966 · Cited by 109
Rudman, S. M., Jameson, M. B., McKeage, M. J., Savage, P. M., Jodrell, D. I., Harries, M., Acton, G. D., Erlandsson, F., & Spicer, J. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2490 · Cited by 109
Asselin‐Paturel, C., Lassau, N., Jm, G., Zhang, J., Gay, F., Bex, F., Hallez, S., Leclère, J., PERONNEAU, P., Mami‐Chouaib, F., et al. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300841 · Cited by 109
Anwer, K., Barnes, M. N., Fewell, J. G., Lewis, D. H., & Alvarez, R. D. (2009) · Gene Therapy · doi:10.1038/gt.2009.159 · Cited by 108
Bortolanza, S., Buñuales, M., Otano, I., González‐Aseguinolaza, G., Ortíz-de-Solórzano, C., Perez, D., Prìeto, J., & Hernández-Alcoceba, R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.9 · Cited by 108
Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12
Zaharoff, D. A., Hoffman, B. S., Hooper, H. B., Benjamin, C. J., Khurana, K. K., Hance, K. W., Rogers, C. J., Pinto, P. A., Schlom, J., & Greiner, J. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1114 · Cited by 107
Self-citationBramson, J. L., Hitt, M., Gauldie, J., & Graham, F. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300508 · Cited by 106
Younes, A., Pro, B., Robertson, M. J., Flinn, I. W., Romaguera, J. E., Hagemeister, F. B., Dang, N. H., Fiumara, P. F., Loyer, E. M., Cabanillas, F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0540 · Cited by 106
Mortarini, R., Borri, A., Tragni, G., Bersani, I., Vegetti, C., Bajetta, E., Pilotti, S., Cerundolo, V., & Anichini, A. (2000) · PubMed · Cited by 105
van Herpen, C. M. L., van der Laak, J. A. W. M., de Vries, I. J. M., van Krieken, J. H., de Wilde, P. C., Balvers, M. G. J., Adema, G. J., & Mulder, P. H. M. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1524 · Cited by 104
Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12
Zaharoff, D. A., Hance, K. W., Rogers, C. J., Schlom, J., & Greiner, J. W. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eb826d · Cited by 103
Self-citationLenzi, R., Rosenblum, M. G., Verschraegen, C. F., Kudelka, A. P., Kavanagh, J. J., Hicks, M. E., Lang, E., Nash, M. A., Levy, L. B., Garcia, M. E., et al. (2002) · PubMed · Cited by 103
Bhatia, S., Longino, N. V., Miller, N. J., Kulikauskas, R. M., Iyer, J. G., Ibrani, D., Blom, A., Byrd, D. R., Parvathaneni, U., Twitty, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0972 · Cited by 103
Barrett, J. A., Cai, H., Miao, J., Khare, P. D., Gonzalez, P., Dalsing-Hernandez, J. E., Sharma, G., Chan, T., Cooper, L. J. N., & Lebel, F. M. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0019-0 · Cited by 101
Hurteau, J. A., Blessing, J. A., Decesare, S. L., & Creasman, W. T. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6255 · Cited by 100
Kishida, T., Asada, H., Satoh, E., Tanaka, S., Shin‐Ya, M., Hirai, H., Iwai, M., Tahara, H., Imanishi, J., & Mazda, O. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301519 · Cited by 98
Novelli, F., Bernabei, P., Ozmen, L., Rigamonti, L., Allione, A., Pestka, S., Garotta, G., & Forni, G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.5.1935 · Cited by 97
Portielje, J. E. A., Lamers, C. H. J., Kruit, W. H. J., Sparreboom, A., Bolhuis, R. L. H., Stoter, G., Huber, C., & Gratama, J. W. (2003) · PubMed · Cited by 97
Greaney, S. K., Algazi, A. P., Tsai, K. K., Takamura, K. T., Chen, L., Twitty, C., Zhang, L., Paciorek, A. T., Pierce, R. H., Le, M. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0359 · Cited by 97
Rodríguez-Madoz, J. R., Prìeto, J., & Smerdou, C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.011 · Cited by 96
Revisiting Interleukin-12 as a Cancer Immunotherapy Agent
Berraondo, P., Etxeberría, I., Ponz‐Sarvisé, M., & Melero, I. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0381 · Cited by 96
Intratumoral Delivery of p2CMVmIL-12 Using Water-Soluble Lipopolymers
Mahato, R. I., Lee, M., Han, S.-O., Maheshwari, A., & Kim, S. W. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0425 · Cited by 94
Gillies, S. D., Lan, Y., Wesolowski, J. S., Qian, X., Reisfeld, R. A., Holden, S. A., Super, M., & Lo, K.-M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.6195 · Cited by 93
Mazzolini, G. D., Qian, C., Xie, X., Sun, Y., Lasarte, J. J., Droździk, M., & Prìeto, J. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700072 · Cited by 93
Soluble Biodegradable Polymer-Based Cytokine Gene Delivery for Cancer Treatment
Maheshwari, A., Mahato, R. I., McGregor, J., Han, S., Samlowski, W. E., Park, J. S., & Kim, S. W. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0105 · Cited by 93
Veinalde, R., Grossardt, C., Hartmann, L., Bourgeois‐Daigneault, M., Bell, J. C., Jäger, D., Kalle, C. V., Ungerechts, G., & Engeland, C. E. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1285992 · Cited by 93
Gene Therapy of Cancer Based on Interleukin 12
Sangro, B., Melero, I., Qian, C., et al. (2005) · Current Gene Therapy · doi:10.2174/156652305774964712 · Cited by 92
Mills, B. N., Connolly, K. A., Ye, J., Murphy, J. D., Uccello, T. P., Han, B. J., Zhao, T., Drage, M. G., Murthy, A., Qiu, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.095 · Cited by 91
Liu, Y., Ehtesham, M., Samoto, K., Wheeler, C. J., Thompson, R. C., Villarreal, L. P., Black, K. L., & Yu, J. S. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700399 · Cited by 87
Gerner, M. Y., Heltemes-Harris, L. M., Fife, B. T., & Mescher, M. F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300652 · Cited by 87
Janat-Amsbury, M. M., Yockman, J. W., Lee, M., Kern, S. E., Furgeson, D. Y., Bikram, M., & Kim, S. W. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.03.015 · Cited by 86
Vijayakumar, G., McCroskery, S., & Palese, P. (2019) · Journal of Virology · doi:10.1128/jvi.01677-19 · Cited by 85
Heller, L. C., Merkler, K. A., Westover, J., Cruz, Y., Coppola, D., Benson, K., DAUD, A. I., & Heller, R. F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2727 · Cited by 84
Leoni, V., Vannini, A., Gatta, V., Rambaldi, J., Sanapo, M., Barboni, C., Zaghini, A., Nanni, P., Lollini, P., Casiraghi, C., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007209 · Cited by 84
Alvarez, R. D., Sill, M. W., Davidson, S. A., Muller, C. Y., Bender, D., Debernardo, R., Behbakht, K., & Huh, W. K. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.571 · Cited by 81
Xu, C., Zhang, Y., Rolfe, A., Hernández, V. M., Guzman, W., Kradjian, G., Marelli, B., Qin, G., Qi, J., Wang, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0483 · Cited by 81
Duan, X., Guan, H., Cao, Y., & Kleinerman, E. S. (2009) · Cancer · doi:10.1002/cncr.24013 · Cited by 79
Alessandrini, F., Menotti, L., Avitabile, E., Appolloni, I., Ceresa, D., Marubbi, D., Campadelli‐Fiume, G., & Malatesta, P. (2019) · Oncogene · doi:10.1038/s41388-019-0737-2 · Cited by 79
Sabel, M. S., Skitzki, J. J., Stoolman, L. M., Egilmez, N. K., Mathiowitz, E., Bailey, N. A., Chang, W.-J., & Chang, A. E. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.03.022 · Cited by 78
Gambotto, A. A., Tüting, T., McVey, D., Kovesdi, I., Tahara, H., Lotze, M. T., & Robbins, P. D. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700013 · Cited by 78
Systemic dissemination of viral vectors during intratumoral injection.
Wang, Y., Hu, J., Krol, A., Li, Y.-P., Li, C., & Yuan, F. (2003) · PubMed · Cited by 77
Roth, J. C., Cassady, K. A., Cody, J. J., Jn, P., Price, K. H., Coleman, J. M., Peggins, J. O., Noker, P. E., Powers, N., Grimes, S. D., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.201 · Cited by 77
Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma
Pham-Nguyen, K. B., Yang, W., Saxena, R., Thung, S. N., Woo, S. L. C., & Chen, S. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990531)81:5<813::aid-ijc24>3.0.co;2-i · Cited by 77
Li, S. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.10.762 · Cited by 76
Lo, K.-M., Yan, L., Lauder, S., Zhang, J., Brunkhorst, B. A., Qin, G., Verma, R., Courtenay-Luck, N. S., & Gillies, S. D. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0203-1 · Cited by 75
Ansari, D., Kristoffersson, S., Andersson, R. E., & Bergenfeldt, M. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1346705 · Cited by 74
Shi, F., Rakhmilevich, A. L., Heise, C. P., Oshikawa, K., Sondel, P. M., Yang, N.-S., & Mahvi, D. M. (2002) · PubMed · Cited by 73
Broderick, L., Yokota, S. J., Reineke, J., Mathiowitz, E., Stewart, C. C., Barcos, M. P., Kelleher, R. J., & Bankert, R. B. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.898 · Cited by 71
Fallon, J. K., Vandeveer, A. J., Schlom, J., & Greiner, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.16137 · Cited by 71
Satoh, T., Saika, T., Ebara, S., Kusaka, N., Timme, T. L., Yang, G., Wang, J., MOURAVIEV, V. B., Cao, G., Fattah, E. M. A., et al. (2003) · PubMed · Cited by 70
Shin, E. J., Wanna, G. B., Choi, B. D., et al. (2007) · The Laryngoscope · doi:10.1097/01.mlg.0000246194.66295.d8 · Cited by 70
Chang, J., Cho, J.-H., Lee, S., Choi, S., Ha, S., & Sung, Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2818 · Cited by 69
Mendiratta, S. K., Quezada, A., Matar, M. M., Wang, J., Hebel, H. L., Long, S., Nordstrom, J. L., & Pericle, F. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300891 · Cited by 68
Petry, H., Brooks, A. R., Orme, A. E., Wang, P., Liu, P., Xie, J., Kretschmer, P. J., Qian, H. S., Hermiston, T. W., & Harkins, R. N. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303037 · Cited by 68
Paoloni, M. C., Mazcko, C. N., Selting, K. A., Lana, S. E., Barber, L. G., Phillips, J., Skorupski, K. A., Vail, D. M., Wilson-Robles, H. M., Biller, B. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129954 · Cited by 67
Hess, S. D., Egilmez, N. K., Bailey, N. A., Anderson, T. M., Mathiowitz, E., Bernstein, S. H., & Bankert, R. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.400 · Cited by 67
(2003) · PubMed · Cited by 67
Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats
DiMeco, F., Rhines, L. D., Hanes, J. S., et al. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.92.3.0419 · Cited by 66
Gu, T., Rowswell-Turner, R. B., Kilinc, M. O., & Egilmez, N. K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-3170 · Cited by 66
Thaker, P. H., Brady, W. E., Lankes, H. A., Odunsi, K. O., Bradley, W. H., Moore, K. N., Muller, C. Y., Anwer, K., Schilder, R. J., Alvarez, R. D., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.001 · Cited by 66
Worth, L. L., Jia, S.-F., Zhou, Z., Chen, L., & Kleinerman, E. S. (2000) · PubMed · Cited by 65
Anwer, K., Kelly, F. J., Chu, C., Fewell, J. G., Lewis, D. H., & Alvarez, R. D. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.07.081 · Cited by 63
Schilbach, K., Alkhaled, M., Welker, C., Eckert, F., Blank, G., Ziegler, H., Sterk, M., Müller, F., Sonntag, K., Wieder, T., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1014760 · Cited by 62
Egilmez, N. K., Jong, Y. S., Iwanuma, Y., Jacob, J. S., Santos, C. A., Chen, F.-A., Mathiowitz, E., & Bankert, R. B. (1998) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050455 · Cited by 62
The Next Challenge in Cancer Immunotherapy: Controlling T-Cell Traffic to the Tumor
Abastado, J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3538 · Cited by 62
Tamura, T., Nishi, T., Goto, T., Takeshima, H., Dev, S. B., Ushio, Y., & Sakata, T. (2001) · Human Gene Therapy · doi:10.1089/104303401750270922 · Cited by 61
Rosa, F., Cochet, M., & Fellous, M. M. (1986) · PubMed · Cited by 61
Wu, C.-J., Tsai, Y.-T., Lee, I., Wu, P., Lu, L., Tsao, W.-S., Huang, Y.-J., Chang, C.-C., Ka, S., & Tao, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1477459 · Cited by 61
Hornick, J. L., Sharifi, J., Khawli, L. A., Hu, P., Biela, B. H., Mizokami, M. M., Yun, A., Taylor, C. R., & Epstein, A. L. (1998) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1998.13.255 · Cited by 60
Manna, S. K., & Aggarwal, B. B. (2000) · Oncogene · doi:10.1038/sj.onc.1203547 · Cited by 60
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
The Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332
IL-12 Family Cytokines in Cancer and Immunotherapy
Mirlekar, B., & Pylayeva-Gupta, Y. (2021) · Cancers · doi:10.3390/cancers13020167 · Cited by 295
Metadata
- Authors
- Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-10-15
- Volume
- 11
- Pages
- 575597-575597
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3093225819
- Cited by
- 431
- References
- 317
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.